ChemBriefCSL Strikes Rare Disease Drug Deal Worth Up to $1.6 Billion With Swiss Firm Alentis
CSL entered a $1.6 billion partnership with Alentis Therapeutics to co-develop lixudebart for rare kidney and liver diseases. The deal includes a $355 million upfront payment and potential milestone p
reuters · 2026-10-04 15:18